bluebird bio

Vertex Pharmaceuticals

Rocket Pharmaceuticals

Sarepta Therapeutics

AVROBIO Inc

Homology Medicines

Generation Bio

Solid Biosciences

REGENXBIO Inc

264 PubMed publications found for bluebird bio

Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Novel VARS1 variants define new clinical and molecular subtypes of a rare neurodevelopmental syndrome.

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

265 PubMed publications found for bluebird bio

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

263 PubMed publications found for bluebird bio

Clinical data comparison for FDA-approved gene therapies in sickle cell disease.

262 PubMed publications found for bluebird bio

261 PubMed publications found for bluebird bio

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

A scoping review of stem cell models of leukodystrophies: advances in understanding pathophysiological mechanisms.

<article class="bts-verified-summary" data-ticker="BLUE">
<p>bluebird bio (BLUE) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>BLUE has 53 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22BLUE%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

bluebird bio (BLUE) — BioTechSigns Verified Summary

bluebird bio (BLUE) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

BLUE has 53 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22BLUE%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11